Treatment with the Topical Antimicrobial Peptide Omiganan in Mild-to-Moderate Facial Seborrheic Dermatitis versus Ketoconazole and Placebo: Results of a Randomized Controlled Proof-of-Concept Trial

Treatment with the Topical Antimicrobial Peptide Omiganan in Mild-to-Moderate Facial Seborrheic Dermatitis versus Ketoconazole and Placebo: Results of a Randomized Controlled Proof-of-Concept Trial

Facial seborrheic dermatitis (SD) is an inflammatory skin disease characterized by erythematous and scaly lesions on the skin with high sebaceous gland activity. The yeast <i>Malassezia</i> is regarded as a key pathogenic driver in this disease, but increased <i>Staphylococcus</...

Full description

Bibliographic Details
Main Authors: Jannik Rousel, Mahdi Saghari, Lisa Pagan, Andreea Nădăban, Tom Gambrah, Bart Theelen, Marieke L. de Kam, Jorine Haakman, Hein E. C. van der Wall, Gary L. Feiss, Tessa Niemeyer-van der Kolk, Jacobus Burggraaf, Joke A. Bouwstra, Robert Rissmann, Martijn B. A. van Doorn
Format: Article
Language:English
Published: MDPI AG 2023-09-01
Series:International Journal of Molecular Sciences
Subjects:
seborrheic dermatitis
omiganan
ketoconazole
<i>Malassezia</i>
<i>Staphylococcus</i>
skin barrier
Online Access:https://www.mdpi.com/1422-0067/24/18/14315

Internet

https://www.mdpi.com/1422-0067/24/18/14315

Similar Items